Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:05 PM
Ignite Modification Date:
2025-12-24 @ 3:05 PM
NCT ID:
NCT06625359
Eligibility Criteria:
Inclusion Criteria:
* ∙Patients with histologically confirmed primary central nervous system lymphoma or secondary CNS lymphoma defined as either synchronous CNS involvement of sys- temic NHL or as a site of recurrence in a patient s with a history of systemic NHL
* Patients who achieved remission after first line chemotherapy and/or WBRT, or who experience relapse of PCNSL/SCNLS.
* Patients who have not previously received therapy with high high-dose chemotherapy and stem cell transplantatitransplantation.
* The performance st atus of the patients should be 2 or less by ECOG performance scale.
* Patients should not have major illness or organ failure incompatible with autologous stem cell transplantation.
* Patients must have adequate hepatic function (serum bilirubin less than 2.0mg/dl, AST and ALT less than three times the upper normal limit)
* Patients must have adequate renal function ( serum creatinin less than 2.0mg/dl)
* Patients must have adequate cardiac function (ejection fraction 45% on echo- cardiogram)
* Patients must have adequate bone marrow function (ANC 1,000/mm 3 and platelet count 75,000/mm 3 ∙ All patients are fully informed about the nature and purpose of this study and informed consent should be given before the start of treatment. All patients should fully understand the right or trial abandon without any disadvantage.
Exclusion Criteria:
* Concurrent history of neoplasm other than CNS lymphoma with life expectancy less than 3 months.
* History of clinically significant cardiac dysfunction (ex. CHF, symptomatic CAD, uncontrolled arrhythmia) or MI within 12 months.
* psychiatric disorders or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible
* significant infection or uncontrolled bleeding
* enrollment of other clinical trials within 4 weeks prior to treatment
* any preexisting medical condition of sufficient severity to prevent full compliance with study
* patient being not willing to or unable to obey study protocol.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
19 Years
Study:
NCT06625359
Study Brief:
Protocol Section:
NCT06625359